MOTS-c Peptide Levels Linked to Mitochondrial Issues in PCOS Women
Background
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting women, characterized by hormonal imbalances, insulin resistance, and metabolic dysfunction. A key aspect of PCOS pathology is often mitochondrial dysfunction, which impairs cellular energy production and contributes to metabolic issues. This study investigates the relationship between levels of the mitochondrial-derived peptide MOTS-c and mitochondrial function in women with PCOS.
Results
The study revealed significantly lower levels of MOTS-c in women with PCOS compared to healthy controls. Specifically, serum MOTS-c concentrations were reduced by approximately 35% (p<0.001) in the PCOS group. Skeletal muscle MOTS-c mRNA expression also showed a 40% decrease (p<0.001) in women with PCOS, indicating a localized deficiency. The most striking finding was a strong inverse correlation between MOTS-c levels and markers of mitochondrial dysfunction, with PCOS patients exhibiting 2.5-fold higher levels of mitochondrial oxidative stress markers and 30% lower ATP production capacity (p<0.01). Furthermore, lower MOTS-c levels were associated with increased insulin resistance (mean HOMA-IR of 3.2 vs 1.8 in controls, p<0.001) and higher BMI (31.5 kg/m² vs 24.2 kg/m², p<0.001) in the PCOS cohort.
Why It Matters
This research highlights MOTS-c as a potential biomarker and therapeutic target for Polycystic Ovary Syndrome (PCOS). The strong association between reduced MOTS-c and mitochondrial dysfunction suggests that restoring MOTS-c levels could improve metabolic health in PCOS patients. Targeting MOTS-c could offer a novel strategy to address the underlying metabolic complications of PCOS, particularly insulin resistance and mitochondrial impairment. Future research should explore MOTS-c supplementation in preclinical models of PCOS and eventually move towards human clinical trials (e.g., Phase I/II) to evaluate its therapeutic efficacy and safety.